Jul 21 2011
A new report (.pdf) showing "research funding for four key HIV prevention options - preventive vaccines, microbicides, PrEP and operations research related to medical male circumcision" - increased in 2010 compared with 2009 "is certainly good news, but we cannot rest on our laurels," Margaret McGlynn, president and CEO of the International AIDS Vaccine Initiative, Zeda Rosenberg, CEO of the International Partnership for Microbicides, and Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, write in a post on the Global Health Magazine's blog. "Funding data in recent years speak to the commitment of donors to this crucial effort. However, capitalizing on the current momentum in HIV prevention R&D will require both sustained and increased commitment," they conclude (7/19).
 This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
|
Semaglutide improves heart health and reduces weight in obese patients, but with side effects